SOSV is a venture capital firm headquartered in New Jersey, focused on seed-to-growth stage investments in sectors such as biotechnology, hardware, robotics, and cross-border software, particularly in Asia. Established in 1995, SOSV operates several global accelerator programs, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet, Food-X for disruptive food technologies, and dlab for blockchain innovations. The firm invests in approximately 150 companies annually and emphasizes a strategy that combines early-stage funding with extensive support, facilitating product development, customer acquisition, and scaling. SOSV's commitment to nurturing revolutionary deep technologies and its proven track record position it among the top 10% of venture capital funds worldwide.
5Y Capital, previously known as Morningside Venture Capital, is a private equity and venture capital firm based in Shanghai, China, with additional offices in Beijing and Hong Kong. Founded in 1992, it specializes in early-stage investments across a wide range of sectors, including healthcare, technology, fintech, consumer services, media, and education. The firm manages approximately USD 3 billion in funds, leveraging investments from prominent sovereign wealth funds, family offices, and other institutional investors. With an initial investment threshold of over USD 500,000 per portfolio company, 5Y Capital focuses primarily on opportunities in China and other emerging markets in Asia and the Pacific. It is a subsidiary of the Morningside Group, which has a long-standing commitment to socially responsible investing and philanthropic initiatives, particularly in education and scientific research.
Versant Ventures is a prominent healthcare investment firm founded in 1999 and headquartered in California. The firm specializes in investing across the healthcare sector, focusing on medical devices, biotechnology, and pharmaceuticals at various stages of company development. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant Ventures emphasizes the discovery and development of novel therapeutics. The firm has cultivated a team with extensive investment, operational, and scientific expertise, allowing for a hands-on approach to building companies. Since its inception, more than 65 companies backed by Versant have successfully achieved acquisitions or initial public offerings.
Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that promotes the development and adoption of new technologies in the region. Over the past 30 years, it has emerged as a prominent provider of seed stage capital, investing more than $170 million in over 1,750 technology companies, many of which have achieved significant industry success. In addition to financial support, Ben Franklin fosters university and industry collaborations to expedite the commercialization of scientific innovations. The organization is dedicated to enhancing the regional entrepreneurial ecosystem, creating jobs, and transforming lives through its initiatives.
IP Group, established in 2001 and based in London, focuses on creating value through the commercialization of intellectual property from research-intensive institutions. The firm excels in identifying suitable intellectual property for commercialization and is adept at developing businesses or forming strategic partnerships to maximize value. With a strong foundation of industry and financial expertise, IP Group has built a solid reputation for delivering consistent results for its companies, partners, and shareholders. By leveraging its extensive knowledge of the commercialization process, IP Group effectively bridges the gap between innovative research and market application, fostering growth and sustainability in its business endeavors.
IMM Investment Corp. is an independent private equity and venture capital firm based in Seoul, South Korea, founded in July 1999. The firm specializes in mezzanine investments and focuses on various investment strategies, including mergers and acquisitions, corporate restructuring, and management buyouts. It targets medium-sized companies in sectors such as information technology infrastructure, wireless communications, healthcare, biotechnology, and manufacturing. IMM Investment allocates its growth stage investments primarily to startups, expansion, and mezzanine funding, with a strong emphasis on IT infrastructure, digital hardware, and content creation. The firm actively participates in management and seeks to invest in companies with strong ratings, particularly in regions like Seoul and surrounding provinces.
OrbiMed is a healthcare-focused investment firm with approximately $5 billion in assets under management. Founded in 1989, the firm aims to invest across a diverse range of healthcare companies, from private startups to large multinational corporations. OrbiMed manages various investment vehicles, including venture capital funds under the Caduceus Private Investments series, as well as public equity funds. The firm specializes in a broad array of sectors within the healthcare industry, such as pharmaceuticals, biotechnology, medical devices, and healthcare services. With a global investment strategy, OrbiMed seeks to make significant investments, typically ranging from $3 million to $150 million, with a preference for taking majority stakes in its portfolio companies. The firm operates offices in major financial centers, including New York, San Francisco, Mumbai, Herzliya, Shanghai, and Luxembourg.
Temasek Holdings, established in 1974, is an investment company based in Singapore with a diverse portfolio of S$242 billion. They are active shareholders in various industries such as transportation, finance, telecommunications, engineering, and property. Temasek's investment themes focus on long-term trends like Transforming Economies and Growing Middle Income Populations. Through subsidiaries like Temasek Capital Management Pte. Ltd. and Temasek Financial (IV) Private Limited, the firm seeks traditional private equity opportunities, mid-stage technology, and life sciences investments globally. Temasek aims to be the investor of choice for companies in Singapore and overseas, with a goal to hold government investments and actively participate in a wide range of sectors to drive growth and value creation.
ARCH Venture Partners is a private equity and venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in investing in seed and early-stage technology companies, with a strong focus on life sciences and biotechnology. ARCH collaborates closely with leading scientists and entrepreneurs to commercialize innovative technologies, particularly those emerging from academic research institutions and national laboratories. The firm has raised ten venture funds totaling over $3 billion and has invested in more than 150 companies, predominantly in the United States, but also in select international markets such as Canada, South Korea, China, and Europe. ARCH prioritizes investments in disruptive technologies across various sectors, including pharmaceuticals, medical devices, and clean technology. The firm typically invests between $50,000 and $150 million per company and seeks to actively participate in their governance by obtaining board representation.
Casdin Capital, LLC is an investment firm specializing in the life sciences and healthcare industry. Founded in 2012 by Eli Casdin, the Chief Investment Officer, Casdin Capital manages a long-short equity fund and invests in early-stage to late-stage private companies within the sector. With approximately $2.2 billion in assets under management as of October 2020, the firm conducts fundamental research to inform its investment decisions.